Payer
ArteraAI Prostate uses digital pathology images from a patient’s biopsy to predict potential long-term outcomes of their prostate cancer.
ArteraAI Prostate forecasts potential long-term outcomes of a patient's prostate cancer biopsy slide based on digital pathology images.
The financing comes on top of the company's $900 million annual research and development investment in the U.S.
The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their overall healthcare, in the third quarter of this year.
The alliance aims to benefit patients with chronic conditions and allow real-time interoperability among healthcare providers, pharmacies and payers.
Maven Clinic introduces male fertility support tools, Scripta Insights announces a tool to locate cost-effective meds, and XRHealth launches a new platform.
Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.
The company began trading on Nasdaq under the ticker symbol HTFL, opening at $19.00 per share.
The Conference Board's principal economic policy analyst PJ Tabit says that while the plan is helpful, it is not a comprehensive framework for how to regulate AI.
Today, 60% of all healthcare payments are in some form of value-based care if you include fee for service with quality metrics for upside bonuses, says Dave Snow, CEO of Cedar Gate Technologies.